Turn to the nation's most objective and informative daily environmental news resource to learn how the United States and key players around the world are responding to the environmental...
By Pat Rizzuto
EPA Administrator Scott Pruitt said he is willing to work with Congress on funding the agency’s process to evaluate chemicals, pesticides, and environmental contaminants for endocrine system health impacts.
The Trump administration’s fiscal year 2018 budget request proposed to zero out funding dedicated to the Endocrine Disruptor Screening Program, but Pruitt told lawmakers during a June 15 hearing that the agency’s Office of Chemical Safety and Pollution Prevention would still continue implementing it.
The program, which is required by law, tests substances for potential effects on the estrogen, androgen and thyroid hormone systems, which affect reproduction, neurological development, and other critical biological functions.
The EPA has completed its review of some substances, including 2,4-D, the active ingredient in several herbicides sold by Dow AgroSciences LLC, and atrazine, a weedkiller made by Syngenta Crop Protection LLC. A full list of company products evaluated by EPA shows the status of the reviews and further testing requests that may be in jeopardy if the program is underfunded or cut completely.
Pesticide and chemical makers support the risk-based approach the EPA uses to identify potential endocrine disruptors, Daniella Taveau, a former trade negotiator with the EPA who now serves as a regulatory and trade specialist for King & Spalding LLP in Washington, told Bloomberg BNA after the administration released its budget blueprint. Without that U.S. approach, a hazard-based method that doesn’t consider exposure levels, which is preferred by some European governments, could affect global trade, she said.
During the hearing, Democrats on a House Appropriations subcommittee criticized Pruitt for the proposed cuts to the endocrine program. Rep. Nita Lowey (D-N.Y.), ranking member of the House Committee on Appropriations, said the program can identify chemicals that have the potential to cause men and women to have a hard time having children, increase incidences of breast cancer, and cause neurodevelopmental delays in children.
“This is the perfect example of senseless cuts that will cost us more in the long run with threats to public health and safety,” Lowey said. “How do you justify eliminating funding for this program?”
Pruitt said the proposed budget stands. “But, you raise a very, very important question,” about a program that has had significant impacts, he said. Pruitt invited ideas from Lowey and other lawmakers about how the program could be addressed or its responsibilities handled in another way.
Rep. Betty McCollum (D-Minn.), said she was pleased to hear Pruitt’s assurances about the importance of the endocrine program, but questioned how the EPA would have “any tools in the tool box” to address endocrine disruptors or other priority programs under the administration’s proposed EPA budget.
Pruitt also told lawmakers the EPA is on track to issue three final chemical regulations by June 22 as required by the 2016 Toxic Substances Control Act amendments.
The three rules would describe the procedures the EPA would use to:
“It also provides certainty to industry that as new chemicals go into commerce EPA will review them within the time lines Congress set,” Pruitt said.
To contact the reporter on this story: Pat Rizzuto in Washington at email@example.com
To contact the editor responsible for this story: Rachael Daigle at firstname.lastname@example.org
Video of Pruitt discussing funding for chemicals and Superfund is available for viewing at https://www.c-span.org/video/?c4674023/pruitt-budget.
Copyright © 2017 The Bureau of National Affairs, Inc. All Rights Reserved.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)